UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.802

Sortiert nach

Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trial

Breast cancer research and treatment, 2022-04, Vol.192 (3), p.593-602

2022

Link zum Volltext

Verfügbarkeit prüfen

TP53 germline mutation may affect response to anticancer treatments: analysis of an intensively treated Li–Fraumeni family

Breast cancer research and treatment, 2015-06, Vol.151 (3), p.671-678

2015

Link zum Volltext

Verfügbarkeit prüfen

Adipocyte fatty acid-binding protein as a novel prognostic factor in obese breast cancer patients

Breast cancer research and treatment, 2010-01, Vol.119 (2), p.367-377

2010

Link zum Volltext

Verfügbarkeit prüfen

Age-related risk factors associated with primary contralateral breast cancer among younger women versus older women

Breast cancer research and treatment, 2019-02, Vol.173 (3), p.657-665

2019

Link zum Volltext

Verfügbarkeit prüfen

Predictors associated with MRI surveillance screening in women with a personal history of unilateral breast cancer but without a genetic predisposition for future contralateral breast cancer

Breast cancer research and treatment, 2017-11, Vol.166 (1), p.145-156

2017

Link zum Volltext

Verfügbarkeit prüfen

Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature

Breast cancer research and treatment, 2010-02, Vol.120 (1), p.119-126

2010

Link zum Volltext

Verfügbarkeit prüfen

Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype

Breast cancer research and treatment, 2012-11, Vol.136 (1), p.153-160

2012

Link zum Volltext

Verfügbarkeit prüfen

Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II–III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance)

Breast cancer research and treatment, 2016-11, Vol.160 (2), p.297-304

2016

Link zum Volltext

Verfügbarkeit prüfen

Impact of chemotherapy, radiotherapy, and endocrine therapy on sick leave in women with early-stage breast cancer during a 5-year period: a population-based cohort study

Breast cancer research and treatment, 2020-08, Vol.182 (3), p.699-707

2020

Link zum Volltext

Verfügbarkeit prüfen

Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy

Breast cancer research and treatment, 2019-08, Vol.177 (1), p.61-66

2019

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy

Breast cancer research and treatment, 2018-04, Vol.168 (2), p.357-364

2018

Link zum Volltext

Verfügbarkeit prüfen

Multivariate machine learning models for prediction of pathologic response to neoadjuvant therapy in breast cancer using MRI features: a study using an independent validation set

Breast cancer research and treatment, 2019-01, Vol.173 (2), p.455-463

2019

Link zum Volltext

Verfügbarkeit prüfen

Prospective open uncontrolled phase I study to define a well-tolerated dose of oral artesunate as add-on therapy in patients with metastatic breast cancer (ARTIC M33/2)

Breast cancer research and treatment, 2017-07, Vol.164 (2), p.359-369

2017

Link zum Volltext

Verfügbarkeit prüfen

HER2-targeted therapy influences CTC status in metastatic breast cancer

Breast cancer research and treatment, 2020-07, Vol.182 (1), p.127-136

2020

Link zum Volltext

Verfügbarkeit prüfen

Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy

Breast cancer research and treatment, 2019-08, Vol.176 (3), p.709-716

2019

Link zum Volltext

Verfügbarkeit prüfen

Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy

Breast cancer research and treatment, 2018-09, Vol.171 (2), p.371-381

2018

Link zum Volltext

Verfügbarkeit prüfen

Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study

Breast cancer research and treatment, 2019-06, Vol.175 (3), p.595-603

2019

Link zum Volltext

Verfügbarkeit prüfen

Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005)

Breast cancer research and treatment, 2013-02, Vol.138 (1), p.99-108

2013

Link zum Volltext

Verfügbarkeit prüfen

Association between financial burden and adjuvant hormonal therapy adherence and persistent use for privately insured women aged 18–64 years in BCBS of Texas

Breast cancer research and treatment, 2018-06, Vol.169 (3), p.573-586

2018

Link zum Volltext

Verfügbarkeit prüfen

Taste and smell perception and quality of life during and after systemic therapy for breast cancer

Breast cancer research and treatment, 2018-07, Vol.170 (1), p.27-34

2018

Link zum Volltext

Verfügbarkeit prüfen

Optimal breast reconstruction type for patients treated with neoadjuvant chemotherapy, mastectomy followed by radiation therapy

Breast cancer research and treatment, 2020-08, Vol.183 (1), p.127-136

2020

Link zum Volltext

Verfügbarkeit prüfen

Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients

Breast cancer research and treatment, 2009-05, Vol.115 (2), p.359-363

2009

Link zum Volltext

Verfügbarkeit prüfen

Frequency of radiation-induced malignancies post-adjuvant radiotherapy for breast cancer in patients with Li-Fraumeni syndrome

Breast cancer research and treatment, 2020-05, Vol.181 (1), p.181-188

2020

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant endocrine therapy non-initiation and non-persistence in young women with early-stage breast cancer

Breast cancer research and treatment, 2023-02, Vol.197 (3), p.547-558

2023

Link zum Volltext

Verfügbarkeit prüfen

Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01–04) for women with stage II/III breast cancer

Breast cancer research and treatment, 2011-06, Vol.127 (2), p.429-438

2011

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 1.802

Suche als RSS-Feed

Aktive Filter

ThemaAged, 80 And Over

Zeitschrift / SerieBreast Cancer Research And Treatment

ThemaAdult

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.802)
Mit Volltextzugriff
(1.802)

Publikationsform

Artikel
(1.802)

Sprache

Englisch
(1.802)
Japanisch
(270)
Russisch
(2)
Norwegisch
(1)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Kollektion

SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(1.802)
MEDLINE
(1.802)
WK Lippincott Williams & Wilkins–Connect here FIRST to enable access
(1.802)
Springer journals
(1.802)
IngentaConnect Journals
(148)
Ingenta E-Journals
(2)
EZB Electronic Journals Library
(1)
Nature Journals Online
(1)

3 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trial

TP53 germline mutation may affect response to anticancer treatments: analysis of an intensively treated Li–Fraumeni family

Adipocyte fatty acid-binding protein as a novel prognostic factor in obese breast cancer patients

Age-related risk factors associated with primary contralateral breast cancer among younger women versus older women

Predictors associated with MRI surveillance screening in women with a personal history of unilateral breast cancer but without a genetic predisposition for future contralateral breast cancer

Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature

Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype

Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II–III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance)

Impact of chemotherapy, radiotherapy, and endocrine therapy on sick leave in women with early-stage breast cancer during a 5-year period: a population-based cohort study

Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy

Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy

Multivariate machine learning models for prediction of pathologic response to neoadjuvant therapy in breast cancer using MRI features: a study using an independent validation set

Prospective open uncontrolled phase I study to define a well-tolerated dose of oral artesunate as add-on therapy in patients with metastatic breast cancer (ARTIC M33/2)

HER2-targeted therapy influences CTC status in metastatic breast cancer

Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy

Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy

Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study

Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005)

Association between financial burden and adjuvant hormonal therapy adherence and persistent use for privately insured women aged 18–64 years in BCBS of Texas

Taste and smell perception and quality of life during and after systemic therapy for breast cancer

Optimal breast reconstruction type for patients treated with neoadjuvant chemotherapy, mastectomy followed by radiation therapy

Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients

Frequency of radiation-induced malignancies post-adjuvant radiotherapy for breast cancer in patients with Li-Fraumeni syndrome

Adjuvant endocrine therapy non-initiation and non-persistence in young women with early-stage breast cancer

Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01–04) for women with stage II/III breast cancer

Aktive Filter

Suchergebnisse filtern